Knowledge Management System of Hefei Institute of Physical Science,CAS
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors. | |
Xu, Nong; Zheng, Yulong; Zhong, Haijun; Zhao, Fuyou; Zhou, Huan; Mao, Chenyu; Lv, Wangxia; Yuan, Meiqin; Qian, Jiong; Jiang, Haiping; Wang, Zishu; Xiao, Cheng; Liu, Ting; Liu, Wei; Li, Baiyong; Xia, Yu | |
2022-06-01 | |
发表期刊 | JOURNAL OF CLINICAL ONCOLOGY |
ISSN | 0732-183X |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Akeso Biopharma, Inc. |
项目资助者 | Akeso Biopharma, Inc. |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000863680300914 |
出版者 | LIPPINCOTT WILLIAMS & WILKINS |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/129922 |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China 2.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Beijing, Peoples R China 4.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 5.Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China 6.Zhejiang Univ, Affiliated Hosp 1, Dept Oncol, Sch Med, Hangzhou, Peoples R China 7.Akeso Biopharma Inc, Zhongshan, Peoples R China |
推荐引用方式 GB/T 7714 | Xu, Nong,Zheng, Yulong,Zhong, Haijun,et al. First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40. |
APA | Xu, Nong.,Zheng, Yulong.,Zhong, Haijun.,Zhao, Fuyou.,Zhou, Huan.,...&Xia, Yu.(2022).First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors..JOURNAL OF CLINICAL ONCOLOGY,40. |
MLA | Xu, Nong,et al."First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.".JOURNAL OF CLINICAL ONCOLOGY 40(2022). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论